Ultimovacs Reports the Completion of Patient Enrolment in P-II Study (FOCUS) of UV1 for Head and Neck Cancer
Shots:
- The patient’s enrolment has been completed & the last patient received the first dose in the P-II study evaluating UV1 + pembrolizumab vs pembrolizumab alone at 10 sites across Germany. The trial was sponsored by Martin-Luther-University Halle-Wittenberg with support from Ultimovacs
- The study focuses to determine the clinical performance of UV1 vaccination as an add-on to standard pembrolizumab treatment. The 1EPs is PFS rate at 6mos. after 1st administration & 2EPs incl. PFS, OS, ORR, DoR & safety with a minimum of 12mos. follow-up, results are expected in H2’24
- UV1 is being evaluated in a broad clinical development program across multiple cancer indications with different biologics & disease stages in combination with different checkpoint inhibitors
Ref: Globe Newswire | Image: Ultimovacs
Related news:- Ultimovacs Reports Results of 24-month Follow-up Study of UV1 + Pembrolizumab for 1L Treatment of Metastatic Malignant Melanoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
